1. Psychotropic medications for highly vulnerable children
- Author
-
Stephanie C Acquilano, Robert E. Drake, Milangel T Concepcion Zayas, Jonathan D. Lichtenstein, Lisa M. Schwartz, Steven Woloshin, Erin R. Barnett, and Jennifer L. McLaren
- Subjects
Male ,medicine.medical_specialty ,Adolescent ,Population ,Psychological intervention ,Vulnerability ,Vulnerable Populations ,03 medical and health sciences ,0302 clinical medicine ,030225 pediatrics ,Humans ,Medicine ,Pharmacology (medical) ,Justice (ethics) ,Child ,education ,Psychiatry ,Pharmacology ,Polypharmacy ,Psychotropic Drugs ,education.field_of_study ,business.industry ,Off-Label Use ,General Medicine ,Mental health ,030227 psychiatry ,Systematic review ,Female ,business ,Psychosocial - Abstract
At least 20% of children in the U.S. are highly vulnerable because they lack healthcare and protection. Several factors produce vulnerability: trauma, disruptions of parenting, poverty, involvement in the juvenile justice and/or child welfare systems, residence in restrictive settings, and problems related to developmental disabilities. These children receive psychotropic medications at high rates, raising numerous concerns.The authors begin this review with a description of the population of highly vulnerable children. They then follow this with a review of the effectiveness and side effects of psychotropic medications for their most common diagnoses, using the highest-quality systematic reviews identified by multiple database searches.Highly vulnerable children receive numerous psychotropic medications with high rates of polypharmacy, off-label use, and long-term use, typically in the absence of adjunctive psychosocial interventions. The current evidence contravenes these trends. Future studies of psychotropic medications in vulnerable children should include long-term effectiveness trials and polypharmacy in conjunction with evidence-based, family-centered, psychosocial treatments.
- Published
- 2018